Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.64 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.64 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070773 | 0.86 | SLC22A12 (0.76) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL9987685 | 0.86 | SLC22A12 (0.75) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL9987734 | 0.84 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL12070371 | 0.83 | SLC22A12 (0.71) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL12070368 | 0.82 | SLC22A12 (0.69) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL12071486 | 0.80 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL12070770 | 0.79 | SLC22A12 (0.69) | SLC22A12 | |
| Verinurad SCHEMBL29362845 | 0.78 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL12070797 | 0.78 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL12070364 | 0.77 | SLC22A12 (0.67) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AREDEA BIOSCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AREDEA BIOSCIENCES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-10919858-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919858-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC (US) | 2021-02-16 | — | — | US | disclosed |
| EP-3611167-A1 | THIOACETATE COMPOUND AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611167-A1 | THIOACETATE COMPOUND AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20190185431-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2019-06-20 | — | — | US | disclosed |
| US-20190185431-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. | 2019-06-20 | — | — | US | disclosed |
| US-10266493-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266493-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-8541589-B2 | Thioacetate compounds, compositions and methods of use | ARDEA BIOSCIENCES, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2585437-A2 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Ardea Biosciences, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011159839-A2 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159839-A2 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130202573-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-10266493-B2 | Thioacetate compounds, compositions and methods of use | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-20210171466-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-10919858-B2 | Thioacetate compounds, compositions and methods of use | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-20130203779-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
| US-20190185431-A1 | THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TXN, TXN2, XDH | SLC22A12 757/4885SLC22A6 477/4885SLC22A11 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.